10 U/ml (OR 2.86, p 0.01) remained the only independent factors to predict ovarian cancer recurrence. Conclusions The present paper proposes the validation of a novel CA125 algorithm aiming to detect recurrent EOC. These data may allow us to investigate novel ways of follow up that do not require a patient's physical attendance at a clinic (virtual follow-up)."/>
Skip to main content

Table 3 Multivariate Cox proportional hazards model predicting recurrence

From: The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: a retrospective study

Variables HR 95% CI   P
CA125 doubling 5.10 1.11 23.43 0.036
FIGO stages 3 or 4 vs stage 1 or 2 1.52 0.28 8.30 0.629
Nadir CA125 levels > 10 U/ml 2.86 1.29 6.37 0.010
Residual disease (any vs. nil) 1.06 0.48 2.33 0.893
Cell type (serous vs. other) 1.52 0.55 4.15 0.417